Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
HTEC vs HELX
Shared holdings
19
HTEC covered by HELX
25.06%
HELX covered by HTEC
25.06%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
HTEC (Jan. 31, 2026)
| Security | Weight | |
|---|---|---|
| MODERNA INC | 2.20% | |
| ARROWHEAD PHARMACEUTICALS INC | 2.18% | |
| GUARDANT HEALTH INC | 2.16% | |
| ADAPTIVE BIOTECHNOLOGIES CORP | 2.13% | |
| PENUMBRA INC | 2.12% | |
| AXOGEN INC | 2.02% | |
| ILLUMINA INC | 2.00% | |
| VERTEX PHARMACEUTICALS INC | 2.00% | |
| TWIST BIOSCIENCE CORP | 1.97% | |
| STRYKER CORP | 1.96% | |
| THERMO FISHER SCIENTIFIC INC | 1.95% | |
| EUROFINS SCIENTIFIC SE (BEARER) | 1.95% | |
| LivaNova PLC ORD GBP1.00 (DI) | 1.89% | |
| SIEMENS HEALTHINEERS AG COMMON STOCK | 1.88% | |
| BOSTON SCIENTIFIC CORP | 1.85% | |
| KONINKLIJKE PHIL | 1.85% | |
| REGENERON PHARMACEUTICALS INC | 1.84% | |
| NATERA INC | 1.83% | |
| NOVANTA INC | 1.82% | |
| IQVIA HOLDINGS INC | 1.80% | |
| LONZA GROUP -REG | 1.78% | |
| ROCHE HOLDINGS AG (GENUSSCHEINE) | 1.75% | |
| CHARLES RIVER LABS INTL INC | 1.73% | |
| QIAGEN NV ORD SHARES | 1.72% | |
| MEDPACE HOLDINGS INC | 1.71% | |
| GLAUKOS CORP | 1.70% | |
| INTUITIVE SURGICAL INC | 1.69% | |
| JD HEALTH INTERN | 1.69% | |
| EXACT SCIENCES CORP | 1.68% | |
| NOVOCURE LTD | 1.66% | |
| GLOBUS MEDICAL INC | 1.66% | |
| GRAIL INC | 1.65% | |
| DANAHER CORP | 1.65% | |
| CAREDX INC | 1.63% | |
| INCYTE CORP | 1.62% | |
| TECAN GROUP AG-R | 1.62% | |
| DIASORIN SPA COMMON STOCK | 1.60% | |
| EDWARDS LIFESCIENCES CORP COMMON STOCK | 1.58% | |
| ARTIVION INC | 1.56% | |
| BECTON DICKINSON AND CO COMMON STOCK | 1.50% | |
| BRISTOL-MYERS SQUIBB CO | 1.50% | |
| ABBOTT LABORATORIES COMMON STOCK | 1.45% | |
| TEMPUS AI INC-A | 1.45% | |
| ALNYLAM PHARMACEUTICALS INC | 1.43% | |
| GE HEALTHCARE TECHNOLOGIES INC WI | 1.42% | |
| BIOMARIN PHARMACEUTICAL INC | 1.41% | |
| AGILENT TECHNOLOGIES INC | 1.38% | |
| OMNICELL INC | 1.37% | |
| IRHYTHM TECHNOLOGIES INC | 1.37% | |
| BIO-RAD LABORATORIES-A COMMON STOCK | 1.36% |
HELX (March 31, 2026)
| Security | Weight | |
|---|---|---|
| GUARDANT HEALTH INC | 6.98% | |
| NATERA INC | 6.86% | |
| KRYSTAL BIOTECH INC | 5.49% | |
| UNITED THERAPEUTICS CORP DEL | 4.79% | |
| INSMED INC | 4.66% | |
| BRIDGEBIO PHARMA INC | 4.35% | |
| LIGAND PHARMACEUTICALS | 3.64% | |
| ASTRAZENECA PLC | 3.50% | |
| ADAPTIVE BIOTECHNOLOGIES CORP | 3.22% | |
| VERTEX PHARMACEUTICALS INC | 3.08% | |
| SAMSUNG BIOLOGIC | 3.08% | |
| MEDPACE HOLDINGS INC | 3.06% | |
| REGENERON PHARMACEUTICALS INC | 2.78% | |
| CORTEVA INC | 2.78% | |
| ALNYLAM PHARMACEUTICALS INC | 2.68% | |
| LILLY ELI and CO | 2.62% | |
| IONIS PHARMACEUTICALS INC | 2.15% | |
| TEMPUS AI INC-A | 1.90% | |
| BIONTECH SE ADR | 1.85% | |
| NEUROCRINE BIOSCIENCES INC | 1.71% | |
| STOKE THERAPEUTICS INC | 1.65% | |
| TWIST BIOSCIENCE CORP | 1.64% | |
| ARGENX SE | 1.58% | |
| PTC THERAPEUTICS INC | 1.52% | |
| TRAVERE THERAPEUTICS INC | 1.45% | |
| CHARLES RIVER LABS INTL INC | 1.20% | |
| CRISPR THERAPEUTICS AG | 1.07% | |
| REPLIGEN CORP | 1.06% | |
| VERACYTE INC | 1.05% | |
| PRAXIS PRECISION MEDICINES INC | 1.03% | |
| GRAIL INC | 1.03% | |
| Sartorius Aktiengesellschaft | 0.99% | |
| DANAHER CORP | 0.96% | |
| THERMO FISHER SCIENTIFIC INC | 0.92% | |
| IQVIA HOLDINGS INC | 0.82% | |
| BEAM THERAPEUTICS INC | 0.81% | |
| JAZZ PHARMA PLC | 0.76% | |
| CATALYST PHARMACEUTICALS INC | 0.76% | |
| CADENCE DESIGN SYSTEMS INC | 0.73% | |
| AGILENT TECHNOLOGIES INC | 0.62% | |
| CAREDX INC | 0.62% | |
| QIAGEN NV | 0.61% | |
| ANAPTYSBIO INC | 0.54% | |
| SAMSUNG EPISHOLD | 0.54% | |
| TARSUS PHARMACEUTICALS INC | 0.50% | |
| ULTRAGENYX PHARMA INC | 0.48% | |
| ARCUTIS BIOTHERAPEUTICS INC | 0.47% | |
| AXSOME THERAPEUTICS INC | 0.46% | |
| GENEDX HOLDINGS CORP-A | 0.44% | |
| RHYTHM PHARMACEUTICALS INC | 0.41% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.